New drug trial aims to ease droopy eyelids and double vision
NCT ID NCT07249632
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests whether telitacicept can improve eye muscle symptoms in people with ocular myasthenia gravis, a condition causing droopy eyelids and double vision. About 120 participants aged 12 to 80 will receive either the drug or a placebo for 24 weeks. The study measures changes in eye-related symptom scores and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Telitacicept (a drug that targets the immune system to reduce disease activity)
- What this could lead to
- If it works, this could provide a new treatment option for people with ocular myasthenia gravis, potentially improving eye muscle symptoms and quality of life.
- What could go wrong
- This is a Phase 3 trial, but it's still experimental. The drug may not work better than placebo, and side effects are possible. Results may not apply to all patients.
Why investors are watching
Remegen is running a Phase III trial of telitacicept in ocular myasthenia gravis, a condition affecting eye muscles, with 120 patients aged 12 to 80. For a small-cap company, this late-stage readout is a major value driver because a positive result could support a new approval and broaden the drug's use beyond its current indications. The trial compares telitacicept against placebo over 24 weeks, measuring changes in eye-related symptom scores.
If it works: If the trial shows telitacicept meaningfully improves ocular symptoms compared to placebo, Remegen could gain a new approved treatment for a niche but underserved patient group. That outcome would likely strengthen the company's pipeline and commercial prospects.
If it fails: Phase III trials often fail, and this one could miss its primary endpoint or show safety problems, which would set back Remegen's plans for this indication. Delays in enrollment or data readout could also hurt investor confidence, given the company's small size and reliance on this program.
AI-written from the trial record. Speculative, and not investment advice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
About 120 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2026
- Expected to finish
-
Feb 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
12 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Voluntarily signed the informed consent form. 2. Age 12 to 80 years, inclusive, male or female. 3. Body weight ≥30 kg. 4. Diagnosis of Myasthenia Gravis (MG) with documented clinical features consistent with the disease. 5. Myasthenia Gravis Foundation of America (MGFA) Clinical Classification of Type I. 6. On a stable standard-of-care (SOC) treatment regimen. Exclusion Criteria: 1. Concomitant autoimmune diseases requiring systemic corticosteroid therapy. 2. Clinically significant laboratory abnormalities. 3. Use of other immunosuppressants (not part of the stable SOC) within 1 month prior to randomization. 4. Presence of an acute or chronic infection requiring treatment. 5. Current active hepatitis or history of severe liver disease. 6. Positive for HIV antibodies. 7. Positive for syphilis antibodies (non-specific or specific). 8. Poorly controlled diabetes mellitus, defined as HbA1c \>9.0% or fasting blood glucose ≥11.1 mmol/L. 9. Subjects with thymoma (classified as ≤ Stage II for benign and ≥ Stage III for malignant according to the Masaoka staging system) . 10. Presence of uncontrolled chronic degenerative diseases, psychiatric disorders, or neurological diseases other than MG that could interfere with study assessments. 11. Other diseases causing ptosis, peripheral muscle weakness, or diplopia (e.g., Graves' ophthalmopathy, blepharospasm, progressive external ophthalmoplegia, muscular dystrophy, brainstem or cranial nerve lesions, etc.). 12. Known allergy to human-derived biological products.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Myasthenia gravis, ocular are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Beijing Hospital
RECRUITINGBeijing, Beijing Municipality, 100000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.